Navigation Links
1960s-era anti-cancer drug points to treatments for Lou Gehrig's disease

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting. Their research showing how the drug prevents clumping of an enzyme linked to ALS appears in the Journal of the American Chemical Society.

Lucia Banci, Ivano Bertini and colleagues explain that ALS causes a progressive loss of muscle control as the nerves that control body movements wither and die. Patients become weak and have difficulty swallowing and breathing, and most die within three to five years of diagnosis. Although some ALS cases are hereditary and run in families, about 90 percent are "sporadic," with the cause unknown. Some research links sporadic ALS to clumping of an antioxidant enzyme called hSOD1. The authors explored whether cisplatin, a chemotherapy drug used since the 1960s that is known to interact with some of the enzyme's amino acids, has any effect on hSOD1 clusters.

The scientists found that in laboratory tests, the anti-cancer drug cisplatin bound readily to the enzyme, preventing hSOD1 from aggregating and dissolving existing bunches. Cisplatin targets sites that can form bonds between hSOD1 after the enzyme loses the atom of copper it normally carries. The scientists note that cisplatin does not prevent the enzyme from performing its normal functions. "From this work it appears that cisplatin is a promising lead compound for the rational design of ALS treatments," the authors say.


Contact: Michael Bernstein
American Chemical Society

Page: 1

Related medicine news :

1. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
2. More Research Points to Long-Term Ills With Bone Drugs
3. Research With Dogs Points to Early Test for Arthritis
4. Study Pinpoints New Abnormality in Athletes Heart
5. Experimental Chemo Combo for Colon Cancer Disappoints
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
8. Study examines treatments for relieving breathing difficulties among patients with lung effusions
9. Researchers make promising discovery in pursuit of effective lymphoma treatments
10. Research May Point to New Obesity Treatments
11. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: